Concentra Group Holdings: Analysts Raise Price Targets Following Increased Guidance
This article was created with the help of artificial intelligence.
Key Takeaways
- Concentra Group Holdings raised revenue and earnings guidance for full-year 2026 on August 11, 2026, and announced succession in management.
- Wells Fargo analyst Stephen Baxter raised Concentra's price target by 43 percent from $28 to $40 while maintaining an Overweight rating.
- Truist Securities analyst David Macdonald raised the price target from $37 to $42 and maintained a Buy rating.
- RBC sees Concentra well-positioned to benefit from a potential increase in manufacturing and construction activities in the AI data center sector.
- In the second quarter of 2026, revenue was $606.03 million and net income was $65.3 million.
Concentra Group Holdings (NYSE:CON) raised revenue and earnings guidance for full-year 2026 on August 11, 2026, and announced succession in management. The stock responded with a gain of 7.6 percent.
Analysts Raise Price Targets Significantly
Wells Fargo analyst Stephen Baxter raised Concentra's price target from $28 to $40 on August 11, 2026, and maintained an "Overweight" rating. A day earlier, Truist Securities analyst David Macdonald had raised the price target from $37 to $42 and retained a "Buy" rating.
The substantial increases followed the announcement of raised full-year guidance. Concentra had previously reported second-quarter 2026 results: revenue came to $606.03 million, net income to $65.3 million.
Potential from Data Center Expansion
RBC sees Concentra in a favorable position to benefit from a potential increase in manufacturing and construction activities in the AI data center sector, according to an analysis from August 10, 2026. Concentra Group Holdings operates a network of healthcare services focused on occupational medicine and emergency care for businesses.
The two price target increases reflect rising analyst confidence in the company's growth prospects. Wells Fargo's increase of 43 percent represents the more significant revaluation. Both analysts continue to rate the stock as a buy.
Comparison with Industry Peers
On August 10, 2026, Yahoo Finance published a comparison between Concentra (CON) and Medpace Holdings (MEDP) from a valuation perspective. The analysis posed the question of which of the two stocks currently represents the better value option, but did not provide a definitive answer.
Sources
- Concentra Group Holdings Parent (CON) Is Up 7.6% After Raising 2026 Guidance And Detailing CEO Succession
- Wells Fargo Maintains Overweight on Concentra Group Holdings, Raises Price Target to $40
- Truist Securities Maintains Buy on Concentra Group Holdings, Raises Price Target to $42
- Concentra Poised to Benefit From AI Data Center Development, RBC Says